The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

CD4<sup>+</sup> T cells, HLA, immune escape, leukemia-associated phenotype, minimal residual disease
dx.doi.org/10.4161/21624011.2014.941737, hdl.handle.net/1765/88237
OncoImmunology
Department of Immunology

van Luijn, M.M, van den Ancker, W, van Ham, S.M, & van de Loosdrecht, A.A. (2014). Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. OncoImmunology, 3(12), 1–3. doi:10.4161/21624011.2014.941737